Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Comments